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Enteroviruses are among the most common and important human pathogens for which there are no 20 
specific antiviral agents approved by the US Food an Drug Administration so far. Particularly, 21 
coxsackievirus infections have a worldwide distribution and can cause many important diseases. 22 
We here report the synthesis of new 14 quinoxaline derivatives and the evaluation of their 23 
cytotoxicity and antiviral activity against representatives of ssRNA, dsRNA and dsDNA viruses. 24 
Promisingly, three compounds showed a very potent and selective antiviral activity against 25 
coxsackievirus B5, with EC50 in the sub-micromolar range (0.3 - 0.06 µM). A combination of 26 
experimental techniques (i.e. virucidal activity, time of drug addition and adsorption assays) and in 27 
silico modeling studies were further performed, aiming to understand the mode of action of the 28 
most active, selective and not cytotoxic compound, the ethyl 4-[(2,3-dimethoxyquinoxalin-6-29 
yl)methylthio]benzoate (6). 30 
 31 
Keywords: antiviral activity; enteroviruses; viral protein VP1; in silico modeling. 32 
 33 
1. Introduction 34 
Viral infections are the major cause of morbidity and mortality in elderly people and young children 35 
worldwide, since in many of these instances no antiviral agents are available in the clinic. 36 
Enteroviruses (EVs), for instance, are pathogens circulating commonly in the environment, with a 37 
seasonal peak during early fall. They belong to the Picornaviridae family, characterized by a single-38 
stranded positive RNA genome surrounded by an icosahedr l capsid around 30 nm in size [1]. 39 
Enteroviruses, which include coxsackievirus A and B, poliovirus and echoviruses, cause systemic 40 
infection in man after ingestion and replication in the gastrointestinal tract [2]. The infection is 41 
normally asymptomatic or mild, but occasionally thevirus spreads to secondary organs leading to 42 
more severe diseases such as aseptic meningitis or my carditis [3, 4]. EVs have long been 43 













the cardiac and skeletal muscles, the central nervous system, the pancreas, the skin and mucous 45 
membranes [5, 6]. Their roles in chronic diseases have also been proposed [7, 8]. Particularly, 46 
coxsackieviruses are non-enveloped viruses classified into two distinct groups A and B. Group A 47 
coxsackieviruses (CV-A) were noted to cause a flaccid paralysis, due to generalized myositis, while 48 
group B coxsackieviruses (CV-B) were linked to spastic paralysis due to focal muscle injury and 49 
degeneration of neuronal tissue. The last group are also prone to infect the heart, pleura, pancreas, 50 
and liver, causing pleurodynia, myocarditis, pericarditis, and hepatitis [9]. In particular, coxsackie B 51 
viruses are an important cause of myopericarditis in children and adults and are associated with the 52 
pathogenesis of the dilated cardiomyopathy [10, 11]. Also a systemic neonatal disease is often 53 
associated with the group B coxsackieviruses [12]. Indeed, coxsackievirus B has also been detected 54 
in the amniotic fluid, placenta, and tissue of unbor  children indicating the ability of pregnant 55 
women to transmit the virus [13]. 56 
Coxsackievirus B5 (CV-B5) is one of the six serotypes of CV-B; it is associated with encephalitis 57 
and myocarditis in immunocompromised children and central nervous system disease in the elderly 58 
adults [14]. 59 
Notwithstanding the incredible efforts and progresses in the antiviral field, conventional drug 60 
therapies targeted against most of ssRNA, dsRNA and dsDNA viral infections remains limited, 61 
often with poor efficacy and incomplete coverage. Bcause of these limitations, basic antiviral drug 62 
discovery programs still constitute the fundamental cornerstone in the development of new and 63 
more effective antiviral arsenals. 64 
In this scenario, the present study investigates the antiviral activities of newly synthesized 65 
quinoxaline derivatives on a panel of selected viruses. Nowadays nitrogen containing heterocyclic 66 
compounds represent one of the largest areas of research in organic chemistry and have been 67 
extensively studied for their broad range of biological activity [15]. Particularly, the quinoxaline 68 
scaffold is described as a bioisoster of quinoline, naphthalene and benzothiophene [16]; specifically, 69 













biological properties [17], including antibacterial [18], antitubercular [19-21], antifungal [22, 23], 71 
antitumoral [24, 25], antinflammatory [26], P-glycopr tein-mediated drug efflux inhibitor [27] and 72 
antiviral activities [17]. Actually various quinoxaline derivatives (Figure 1) were investigated for 73 
their activity against viruses such as HSV-1 (compound A) [28], influenza (compound B) [29], 74 
HIV-1 (compound C and compound D) [30, 31]. Notably, compound D, equally functionalized on 75 
positions 6 and 7 and bearing an aliphatic chain in position 2, is endowed with selective anti-HIV-1 76 
activity, showing an EC50 = 0.22 ± 0.08 µg/ml. 77 
In this paper we present a series of 14 new quinoxaline derivatives (2a-e, 3-11) which structures are 78 
reported in Figure 2. 79 
All compounds were tested against a selected panel of ssRNA, dsRNA and dsDNA viruses, which 80 
includes several important human pathogens such as Human immunodeficiency virus (HIV-1) and 81 
Respiratory syncytial virus (RSV), for which the efficacy of therapeutic agents is unsatisfactory. 82 
Quite importantly, among the whole set of the new quinoxaline derivatives one particular 83 
compound, derivative 6, showed a remarkable activity against CV-B5 virus (EC50 = 0.09 µM) and 84 
selectivity, with absence of cytotoxicity (CC50 > 100 µM) towards the Vero-76 cells. Accordingly, 85 
this compound was selected for further experimental/i  silico investigations aimed at determining 86 
its mechanism of action. In particular, time-of-drug-addition studies revealed that compound 6 87 
might interfere with the earliest stages of viral replication while computer-assisted molecular 88 
simulations highlighted the existence of multiple hydrophobic, polar and hydrogen bond 89 
interactions between the compound and the external viral capsid protein (VP1). 90 
 91 
2. Results and discussion 92 
2.1. Chemistry 93 
Quinoxaline derivatives 2a-e, 3-5 were prepared according to the chemical pathways report d in 94 













Briefly, the key intermediate 6-(bromomethyl)-2,3-dimethoxyquinoxaline was obtained following 96 
the procedures described by Loriga et al. [32]. Its reaction with the appropriate benzenethiol 97 
derivative derivatives (1a-d) was carried out in DMF at 70 °C to give the expected compounds 2a-98 
d. Condensation between the same intermediate and the pyridine-2-thiol (1e) in DMF, in presence 99 
of Cs2CO3, gave the expected derivative 2e. From compound 2d via basic hydrolysis the 100 
corresponding carboxylic acid 3 was obtained. This compound was amidified with L-glutamic acid 101 
diethyl ester hydrochloride in DMF in presence of triethylamine (TEA) and diethyl dicarbonate 102 
(DEPC) to give derivative 4. The free acid 5 was finally obtained from compound 4 by alkaline 103 
hydrolysis. 104 
Compounds 6 and 8 were obtained by an alternative pathway using a solution of diethyl 4,4’-105 
dithiodibenzoate (12a) or diethyl 6,6’-dithionicotinate (12b) treated with NaBH4 under nitrogen. 106 
The unisolated sodium thiolate derivatives, in presence of 6-(bromomethyl)-2,3-107 
dimethoxyquinoxaline, react in DMF to give, respectively, the benzoate derivative 6 and the 108 
nicotinate derivative 8 with good yields. Ester hydrolysis under basic conditions gave the 109 
corresponding acid derivatives 7 and 9. Amide derivative 10 was subsequently obtained for reaction 110 
of the corresponding free acid 9 with diethyl L-glutamate. Finally, alkaline hydrolysis of amide 111 
compound 10 gave the corresponding L-glutamic acid derivative 11. 112 
 113 
2.2. Biology 114 
All synthesized quinoxalines derivatives were tested in cell-based assays against representative of 115 
several RNA and DNA virus families. The results arereported in the Table 1. Compounds that 116 
haven’t showed any antiviral activity or cytotoxicity are not present in the table. 117 
 118 
Table 1. Antiviral activity of quinoxaline derivatives against RNA and DNA viruses and cytotoxicity against 119 













































>100 >100 >100 >100 >100 >100 >100 
2e 28 >28 >100 >100 >100 >100 >100 >100 >100 
4 60 >60 >100 >100 >100 >100 >100 >100 >100 
6 >100 >100 >100 >100 >100 >100 >100 
0.09 ± 0.01 
S.I. >1111 
>100 
7 68 >68 >100 >100 65 >65 65 
0.06 ± 0.01 
S.I.= 1083 
>65 
8 >100 >100 >100 >100 >100 >100 >100 
0.3 ± 0.05 
S.I. >333 
>100 
9 >100 >100 >100 >100 >100 >100 90 
3.8 ± 0.5 
S.I.= 23 
>90 
10 19 >19 >100 
10 ± 1.4 
S.I. >10 












  >100 1.1 ± 0.1 >100 
1.9 ± 
0.1 
   




Data represent mean values for three independent determinations. Standard deviations are reported for the more 
active compounds. Also for the others values the variation was less than 15%. 
aCompound concentration (µM) required to reduce the proliferation of mock-infected MT-4 cells by 50%. 
bCompound concentration (µM) required to achieve 50% protection of MT-4 cells from HIV-1 induced 
cytopathogenicity. d,fCompound concentration (µM) required to achieve 50% protection of MDBK and BHK cells 
from BVDV-induced(d) and YFV or Reo-1-induced cytopathogenicity(f). c,e,gCompound concentration (µM) required 
to reduce the viability of mock-infected MDBK(c), BHK(e) and Vero-76(g) cells by 50%. h,iCompound concentration 
(µM) required to reduce the plaque number of CV-B5(h) and Sb-1, RSV, VSV, VV, HSV-1(i) by 50% in Vero-76 
monolayers. 
S.I. = Selectivity index (CC50/EC50) 
 122 
As seen from Table 1, compound 10 showed a moderate activity against BVDV (10 µM) and CV-123 
B5 (56 µM). A selective anti-HIV-1 activity, although not very potent (EC50 = 36 µM), was found 124 













activity (EC50 = 0.06 - 3.8 µM) against CV-B5. For compounds bearing a functionalized phenyl 126 
moiety, best results were obtained when a carboxylic group is located on position 4: the benzoate 127 
derivative 6 and its acidic derivative 7 emerged for their potency (0.09 and 0.06 µM, respectively) 128 
and selectivity. For the nicotinate series, again a carboxylic group on the aromatic side ring in para 129 
position to the thiomethyl chain led to the best reults. However, in this case, the ester 8 was found 130 
almost 13 times more potent than the corresponding acid 9 (0.3 and 3.8 µM, respectively). Since 131 
compound 6 showed the most potent and highest selective activity against CV-B5 (EC50 = 0.09 ± 132 
0.01 µM), and no cytotoxicity against mammalian cells [selectivity index (S.I.) >1000], it was 133 
selected for further characterization.  134 
Accordingly, the antiviral activity of 6 was investigated in a yield reduction assay, in order to 135 
ascertain the reduction of virus titre in the presence of the active compound during a single round of 136 
viral infection. Not cytotoxic concentrations of 20, 4, 0.8 and 0.16 µM were used and a dose-137 
dependent reduction of virus titre was observed, with a significant reduction of titre already at very 138 
low concentrations (Figure 3). 139 
The potential virucidal activity of 6 was also investigated, incubating a CV-B5 solution c taining 140 
5×105 PFU/ml for 1 hour at 37 °C with two concentrations of compound (4 and 20µM). Compound 141 
6 failed to affect the CV-B5 infectivity (data not showed), suggesting that the inhibition of CV-B5 142 
replication observed in cell-based assays is not due to the infectivity inactivation of virions, but can 143 
be ascribed to an interference of compounds with the viral life cycle. 144 
Experiments designed to test the mechanism of action of 6 under a single cycle conditions on 145 
intracellular virus replication showed (Figure 4) prominent inhibitory activity in decreasing plaque 146 
formation between 0 and 2 hours post infection.  147 
Pretreatment with 6 or addition of 6 simultaneously to infection, followed by the removal of the 148 
sample after two hours, did not result in virus titre reduction (data not showed). On the contrary, the 149 
addition of 6 simultaneously or at 2 hours post infection significantly reduces the virus titre, while 150 













titre, in analogy with the untreated control. These data suggest that 6 inhibits CV-B5 infection by 152 
targeting the early events of attachment, entry or uncoating.  153 
To better define the process of inhibition, the kinetics of virus adsorption in the presence of 6 was 154 
next evaluated. As a matter of fact, low-temperature reatment allows binding of viruses to the cell 155 
surface receptors but prevents the internalization of virus particles into the cells [33, 34]. 156 
Accordingly, Vero-76 cells were incubated with CV-B5 (m.o.i. = 0.1) and 6 for different times at 4 157 
°C, using compound concentrations of 20 and 4µM, respectively. The treatment with compound 6 158 
did not result in detectable reduction of the virus titre in comparison to untreated infected control, 159 
suggesting that inhibition occurs after the adsorpti n step. 160 
 161 
2.3. Modeling results 162 
Given all these experimental evidences and the further observation that the activity of 6 towards 163 
CV-B5 is approximately 10 time less higher (EC50 = 0.09 µM) that the one measured for the same 164 
cell line treated with pleconaril (EC50 = 0.005 µM, Table 1), the hypothesis that these two 165 
compounds might exert a similar mechanism of action as viral capsid protein binders was 166 
formulated. Indeed, similarly to more intensively studied and characterized Rhinovirus, the CV-B 167 
virion structure exhibits an icosahedral symmetry with a diameter size of approximately 30 nm [35]. 168 
Four capsid proteins (VP1-VP4) comprise the virion structure, VP1-VP3 being three external capsid 169 
proteins while protein VP4 is located on the inside of the capsid shell. Accordingly, a large cleft 170 
(aka as canyon) on each of the icosahedral faces of the capsid is the site for interaction with the host 171 
cell receptor [36]. Below this canyon, a hydrophobic pocket is present that in nature, at least for 172 
Rhinovrus, is occupied by a ‘pocket factor’, proposed to be a lipid or fatty acid [37]. This pocket 173 
has been implicated in the conformational changes that VP1 needs to undergo during infection of 174 
the host cell [38]. A panel of rhinovirus inhibitors, referred to as capsid binders (e.g. pleconaril 175 
(Schering-Plough) and vapendavir (Biota Pharmaceutials)), are known to insert into this 176 













Under this perspective, the validity of postulated molecular mechanism of action of 6 was checked 178 
via computer-assisted molecular simulations. Figure 5 offers a global view of the molecular 179 
dynamics (MD) optimized VP1-VP4 capsid protein system in complex with 6. 180 
The relevant MM/PBSA analysis yielded a good binding affinity of the molecule for the protein 181 
(∆Gbind = -9.80 ± 0.31 kcal/mol, corrsponding to a calculated value of EC50,calc = 0.13 µM), in 182 
agreement with its inhibition activity (Table 1). The main favorable contribution to ∆Gbind is 183 
provided by the van der Waals (-37.12 ± 0.08 kcal/mol) and electrostatic (-19.57 ± 0.14 kcal/mol) 184 
components in the gas phase, while the solvation (+20.33 ± 0.12 kcal/mol) and entropic (+26.56 ± 185 
0.24 kcal/mol) components oppose binding. 186 
The specific VP1/6 binding mode (Figure 6(A)) was analyzed by a per-residue decomposition of the 187 
enthalpic component of the free energy of binding ∆Hbind,res. These data (Figure 6(B)) revealed that 188 
in the VP1/6 complex the compound hydrocarbon scaffold established mostly hydrophobic 189 
interactions with VP1 residues I94, L106, F114, L116, L118, Y191, and M215.  190 
 191 
Compound 6 is further permanently hydrogen-bonded to the hydroxyl group of T96 via one of the 192 
quinoxaline nitrogen atom (average dynamic length (ADL) = 3.12 ± 0.04 Å) and to donor 193 
guanidinic group of R103 by its acceptor methoxyl oxygen (ADL =  2.99 3.12 ± 0.05 Å). This 194 
analysis further identified a π-π interaction through a t-shape conformation between th  substituted 195 
phenyl ring of 6 and the aromatic side chain of F239, and a π-c tion bond involving the quinoxaline 196 
aromatic ring and the positive charged R97. As it can be seen from Figure 6(B), all the involved 197 
residues provided a substantial contribution in stabilizing the intermolecular complex enthalpy since 198 
all ∆Hbind,res values higher than |0.75 kcal/mol|, suggesting a quite strong interaction of the VP1 viral 199 
protein with compound 6. 200 
 201 













In this work we reported the synthesis of new quinoxaline derivatives and the determination of their 203 
antiviral activity against a panel of representative ssRNA+, ssRNA-, dsRNA and DNA viral 204 
families, cytotoxicity against different cell lines (MT-4, MDBK, BHK and Vero-76). Among all 205 
compounds, three molecules resulted endowed negligible cytotoxicity and strong and highly 206 
selective activity against the coxsackievirus CV-B5, with EC50 values in the range 0.3 – 0.06 µM. 207 
In this small set, compound 6, (EC50 = 0.09 µM and SI >100) was selected for further 208 
experimental/computational investigations aimed at assessing its possible molecular-based 209 
mechanism of viral replication inhibition. 210 
To the purpose, a series of experiments including virucidal activity, time of addition and virus 211 
adsorption assays were first carried out. The results of these experiments suggested that 6 did not 212 
interfere with the viral attachment to cell receptors, but, rather, it prevented infection by targeting 213 
the subsequent penetration step or an early event during the life cycle. Molecular simulations 214 
revealed that a possible viral target for compound 6 is the viral capsid protein VP1. In analogy with 215 
other molecules such as pleconaril (which exhibits only a 10-times higher  EC50 value with respect 216 
to 6), the potent quinoxaline derivative 6 can favourably insert into a hydrophobic pocket of the 217 
VP1 chain of the capsid protomer implicated in the protein conformational changes during infection 218 
of the host cell. Accordingly, by locking the pocket into a ligand-bond conformation may prevents 219 
the internalization of virus particles. 220 
Coxsackieviruses B are members of Enterovirus genus (Picornaviridae family) and represent 221 
important human pathogens that cause both acute and chronic diseases in infants, young children 222 
and immunocompromised individuals. Until now, there is no enterovirus-specific vaccine or 223 
therapeutic reagent available for clinical use. Our st dies show that the present new quinoxaline 224 
derivatives, possessing high activity and selectivity accompanied with very low cytotoxicity may 225 
serve as a good starting point for the development of ovel drugs for the treatment of infections by 226 














4. Experimental 229 
4.1. Chemistry 230 
Melting points were carried out with a Köfler hot stage or Digital Electrothermal melting point 231 
apparatus. Infrared spectra were recorded as nujol mulls with a Perkin-Elmer 781. Nuclear magnetic 232 
resonance (1H-NMR and 13C-NMR) spectra were determined in CDCl3 or DMSO-d6 and were 233 
recorded with a Bruker Avance III 400 NanoBay. Chemical shifts are reported in parts per million 234 
(ppm) downfield from tetramethylsilane (TMS) used as internal standard. Splitting patterns are 235 
designated as follows: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; br s, broad singlet; 236 
dd, double doublet.  237 
Mass spectra (MS) were performed on combined Liquid Chromatograph-Agilent 1100 series Mass 238 
Selective Detector (MSD). Analytical thin-layer chromatography (TLC) was performed on Merck 239 
silica gel F-254 plates. Pure compounds showed a single spot in TLC. For flash chromatography, 240 
Merck silica gel 60 was used with a particle size 0.04 -0.063 mm (230-400 mesh ASTM). 241 
Elemental analysis were performed on a Perkin-Elmer 2400 instrument and the results were within 242 
± 0.4% of theoretical values. 243 
4.1.2. Starting material and known intermediates 244 
Key intermediates 6-(bromomethyl)-2,3-dimethoxyquinoxaline, diethyl 4,4'-dithiodibenzoate (12a) 245 
and diethyl 6,6'-dithiodinicotinate (12b) were prepared according to the procedures describd in the 246 
literature [32, 39]. Benzenethiol derivatives (1a-d) and the pyridine-2-thiol (1e) were commercially 247 
available. Details of synthesis of each compound are following provided.  248 
4.1.3. General procedure for the preparation of 6-[(het)arylthiomethyl]quinoxalines 249 
derivatives 2a-e. 250 
Equimolar amounts (2 mmol) of 6-(bromomethyl)-2,3-dimethoxyquinoxaline and the suitably 251 
benzenethiol derivative (1a-d) or pyridine-2-thiol (1e) were stirred in dry DMF (8 ml) with an 252 













precipitated as solids, which were collected by filtration and washed with water. All compounds, 254 
obtained as light colored powders, were purified by recrystallization from EtOH/H2O.  255 
4.1.3.1. 2,3-dimethoxy-6-[(4-methoxyphenyl)thiomethyl]quinoxaline (2a). Yield 83%. M.p. 90-91 256 
°C. νmax cm
-1: 1600; 1220; 1090; 1035. λmax nm: 331; 316; 248; 214; 203. 
1H-NMR (DMSO-d6 ) δ: 257 
7.67 (1H, d, J8,7=8.4 Hz, H-8), 7.65 (1H, s, H-5), 7.36 (1H, d, J=8.4 Hz, H-7), 7.26 (2H, d, J=8.6 258 
Hz, H-3’,5’), 6.77 (2H, d, J=8.6 Hz, H-2’,6‘), 4.14 (3H, s, OCH3), 4.49 (2H, s., CH2), 4.12 (3H, s, 259 
OCH3), 3.77 (3H, s, 4’-OCH3). 
13C-NMR (DMSO-d6) δ: 157.03 (C), 149.12 (C), 148.98 (C), 136.23 260 
(C), 135.54 (C), 135.36 (C), 130.42 (2 CH), 127.50 (CH), 127.02 (C), 126.21 (CH), 125.95 (CH), 261 
114.53 (2 CH), 54.79 (CH3), 53.75 (2 CH3), 34.89 (CH2). LC/MS: 343 (M + H). Anal. Calcd for 262 
C18H18N2O3S C, 63.14; H, 5.30; N, 8.18; S, 9.36. Found C, 63.20; H, 5.28; N, 8.12; S, 9.42. 263 
4.1.3.2. 6-[(3,4-dichlorophenyl)thiomethyl]-2,3-dimethoxyquinoxaline (2b). Yield 89%. M.p. 76-77 264 
°C. νmax cm
-1: 1600; 1225; 1130; 1090; 1035; 800. λmax nm: 330; 316; 249; 211. 
1H-NMR (DMSO-265 
d6) δ: 7.70 (1H, d, J=8.4 Hz, H-8), 7.65 (1H, s, H-5), 7.45 (1H, d, J=1.8 Hz, H-2’), 7.39 (1H, d, 266 
J=8.4 Hz, H-7), 7.28 (1H, d, J=8.2 Hz, H-5’), 7.09 (1H, d, J=8.2 Hz, H-6’), 4.46 (2H, s, CH2), 4.00 267 
(6H, s, 2,3-OCH3). 
13C-NMR (DMSO-d6) δ: 155.14 (C), 154.98 (C), 137.25 (C), 136.30 (C), 135.65 268 
(C), 135.50 (C), 131.42 (C), 130.55 (CH), 129.18 (CH), 128.25 (C), 128.11 (CH), 127.53 (CH), 269 
126.11 (CH), 125.90 (CH), 53.87 (2 CH3), 35.92 (CH2). LC/MS: 381 (M + H). Anal. Calcd for 270 
C17H14Cl2N2O2S: C, 53.55; H, 3.70; Cl, 18.60; N, 7.35; S, 8.41. Found C, 53.60; H, 3.67; Cl, 18.70; 271 
N, 7.34; S, 8.37. 272 
4.1.3.3. 2,3-dimethoxy-6-[(naphthalen-2-yl)thiomethyl]quinoxaline (2c). Yield 24%. M.p. 91-92 °C. 273 
νmax cm
-1: 1600; 1530. λmax nm: 330; 316; 249; 216. 
1H-NMR (CDCl3) δ: 7.77-7.70 (6H, m, arom), 274 
7.51-7.45 (4H, m, arom), 4.37 (2H, s, CH2), 4.15 (3H, s, CH3O), 4.13 (3H, s, CH3O). 
13C-NMR 275 
(CDCl3) δ: 150.12 (C), 149.96 (C), 137.10 (C), 136.39 (C), 136.09 (C), 133.71 (C), 133.67 (C), 276 
131.94 (C), 128.40 (CH),  127.90 (CH), 127.76 (CH), 127.69 (CH), 127.59 (CH),127.18 (CH), 277 













(M + H). Anal. Calcd for C21H19N2O2S: C, 69.59; H, 5.01; N, 7.73; S, 8.85. Found C, 69.65; H, 279 
5.11; N, 7.64; O, 8.76; S, 8.88 280 
4.1.3.4. Methyl 2-[(2,3 dimethoxyquinoxalin-6-yl)methylthio]benzoate (2d). Yield 85%. M.p. 142-281 
143 °C. νmax cm
-1: 1720; 1580; 1220; 1115; 1070; 1000. λmax nm: 330; 315; 248; 213. 
1H-NMR 282 
(DMSO-d6) δ: 7.89 (1H, d, J=7.2 Hz, H-6’), 7.80 (1H, s, H-5), 7.69 (1H, d, J=8.0 Hz, H-7), 7.59-283 
7.502 (2H, m, H-8 + H-5’), 7.22 (1H, m, H-4’), 4.40 (2H, s, CH2), 4.01 (6H, s, 2 OCH3), 3.81 (3H, 284 
s, OCH3). 
13C-NMR (DMSO-d6) δ: 166.05 (C), 149.94 (C), 149.76 (C), 140.53 (C), 136.37 (C), 285 
135.64 (C), 135.35 (C), 132.64 (CH), 130.70 (CH), 127.79 (CH), 127.05 (C), 126.25 (CH), 126.09 286 
(CH), 126.05 (CH), 124.32 (CH), 53.89 (2 CH3), 52.06 (CH3), 35.30 (CH2). LC/MS: 371 (M + H). 287 
Anal. Calcd for C19H18N2O4S: C, 61.61; H, 4.90; N, 7.56; S, 8.65. Found C, 61.70; H, 4.83; N, 7.58; 288 
S, 8.57 289 
4.1.3.5. 2,3-dimethoxy-6-[(pyridin-2-yl)thiomethyl]quinoxaline (2e). Yield 90%. M.p. 118-119 °C. 290 
νmax cm
-1: 1580. λmax nm: 330; 315; 302; 212; 196. 
1H-NMR (DMSO-d6) δ: 8.48 (1H, d, J=4.4 Hz, 291 
H-6’), 7.76 (1H, s, H-5), 7.68-7.63 (2H, m, H-8 + H-4’), 7.56 (1H, d, J=7.2 Hz, H-7), 7.33 (1H, d, J 292 
= 8.4 Hz, H-3’), 7.13 (1H, m, H-5’), 4.59 (2H, s, CH2), 4.01 (6H, s, 2 OCH3). 
13C-NMR (DMSO-d6) 293 
δ: 157.72 (C), 149.93 (C), 149.70 (C), 149.39 (C), 136.96 (C), 136.74 (CH), 136.31 (C), 135.53 (C), 294 
127.69 (CH), 126.02 (CH), 125.73 (CH), 121.69 (CH), 120.03 (CH), 53.88 (2 CH3), 32.80 (CH2). 295 
LC/MS: 314 (M + H). Anal. Calcd for C16H15N3O2S: C, 61.32; H, 4.82; N, 13.41; S, 10.23. Found 296 
C, 61.26; H, 4.78; N, 13.35; S, 10.27. 297 
4.1.4. General procedure for the preparation of ethyl 4-[(2,3-dimethoxyquinoxalin-6-298 
yl)methylthio]benzoate (6) and ethyl 6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinate 299 
(8)  300 
NaBH4 (2.5 mmol) was added to a solution of diethyl 4,4’-dithiodibenzoate (12a) or diethyl 6,6’-301 
dithionicotinate (12b) (2.50 mmol) in 25 ml of absolute ethanol under N2. The corresponding 302 













2,3-dimethoxyquinoxaline (3.00 mmol) in 10 ml of DMF. The mixture was stirred, at room 304 
temperature, for 5 h. After dilution with water the precipitated products were collected and washed 305 
with water. Compounds 6 and 8 were obtained as white powder and were further purified by 306 
crystallization from EtOH/H2O. 307 
4.1.4.1. Ethyl 4-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoate (6). Yield 64%. M.p. 130-131 308 
°C νmax cm
-1: 1705; 1225; 1175; 1090. λmax nm: 329; 315; 301; 295; 247; 211. 
1H-NMR (DMSO-d6) 309 
δ: 7.83 (2H, d, J = 8.8 Hz, H-2’ + H-6’), 7.73 (1H, s, H-5), 7.70 (1H, d, J=8.4 Hz, H-8), 7.59 (1H, d, 310 
J = 8.4 Hz, H-7), 7.48 (2H, d, J = 8.8 Hz, H-3’ + H-5’), 4.53 (2H, s, CH2S), 4.27 (2H, q, 311 
OCH2CH3), 4.02 (6H, m, 2 CH3), 1.28 (3H, t, CH3). 
13C-NMR (DMSO-d6) δ: 165.89 (C), 150.02 312 
(C), 149.83 (C), 143.25 (C), 136.33 (C), 135.66 (C), 135.61 (C), 129.48 (2 CH), 127.61 (CH), 313 
126.59 (CH), 126.52 (C), 126.15 (CH), 125.89 (2 CH), 60.60 (CH2), 53.92 (2 CH3), 34.86 (CH2), 314 
14.11 (CH3).  315 
4.1.4.2. Ethyl 6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinate (8). Yield 95%. M.p. 105-106 316 
°C. νmax cm
-1: 1720; 1585. λmax nm: 329; 315; 302; 248; 211. 
1H-NMR (DMSO-d6) δ: 8.94 (1H, s, 317 
H-6’), 8.06 (1H, d, J=8 Hz, H-4’), 7.77 (1H, s, H-5), 7.67 (1H, d, J=8.4 Hz, H-7), 7.59 (1H, d, J=8 318 
Hz, H-3’), 7.47 (1H, d, J=8.4 Hz, H-8) 4.65 (2H, s, CH2S), 4.31 (2H, q, CH2CH3), 4.01 (6H, s, 2 319 
CH3O), 1.31 (3H, t, CH3CH2). 
13C-NMR (DMSO-d6) δ: 167.64 (CO), 164.53 (C), 163.73 (C), 320 
149.93 (CH), 149.76 (C),136.69 (CH), 136.30 (2 C), 135.63 (C), 127.71 (CH), 126.11 (CH), 125.88 321 
(CH), 121.92 (C), 121.23 (CH), 60.94 (CH2), 53.89 (2 CH3), 32.97 (CH2), 14.04 (CH3). LC/MS: 322 
386 (M + H). Anal. Calcd for C19H19N3O4S: C, 59.21; H, 4.97; N, 10.90; S, 8.32. Found C, 59.17; 323 
H, 5.03; N, 10.85; S, 8.44. 324 
4.1.5. General procedure for the preparation of 2 and 6-[(2,3-dimethoxyquinoxalin-6-325 
yl)methylthio]benzoic acids (3,7), and 6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinic 326 













A mixture of 2 mmol of the suitable ester (2d,6,8) in 30 ml of hydroalcoholic solution 1:2 and 10 328 
ml of 1N NaOH was stirred at 70° C, for 7 h. After cooling, the ethanol was evaporated in vacuo 329 
and the alkaline aqueous solution was diluted with ater and made acidic using HCl 2M. The 330 
product obtained by precipitation was collected andwashed with water. Acid derivatives 3 and 9 331 
were purified by crystallization from EtOH/H2O, while derivative 7 by flash cromatography (eluant: 332 
mixture CHCl3-MeOH 95:5). 333 
4.1.5.1. 2[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoic acid (3). Yield 82%. M.p. 241-242 °C. 334 
νmax cm
-1: 1690; 1590; 1225; 1090; 1060; 995. λmax nm: 330; 316; 249; 215. 
1H-NMR (DMSO-d6) 335 
δ: 7.88 (1H, d, J=7.6 Hz, H-6’), 7.81 (1H, s, H-5), 7.67 (1H, d, J=8.4 Hz, H-7), 7.57 (1H, d, J=7.2 336 
Hz, H-4’), 7.50-7.47 (1H, m, H-3’), 7.20-7.10 (1H, m, H-5’), 4.45 (2H, s, CH2S), 4.00 (6H, s, 2 337 
CH3O. 
13C-NMR (DMSO-d6) δ: 167.88 (CO), 150.36 (C), 150.17 (C), 141.34 (C), 136.88 338 
(C),136.08 (C), 135.91 (C), 132.77 (CH), 131.40 (CH), 128.30 (CH), 128.20 (C), 126.52 (2 CH), 339 
126.21 (CH), 124.48 (CH), 54.34 (2 CH3), 35.75 (CH2). LC/MS: 357 (M + H). Anal. Calcd for 340 
C19H16N2O4S: C, 60.66; H, 4.53; N, 7.86; S, 9.00. Found C, 60.59; H, 4.55; N, 7.80; S, 9.08. 341 
4.1.5.2. 4-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoic acid (7). Yield 47%. M.p. 195-196 342 
°C. νmax cm
-1: 1710; 1590; 1215; 1090; 990. λmax nm: 330; 316; 290; 248; 212. 
1H-NMR (DMSO-343 
d6) δ: 7.82 (2H, d, J=8.4 Hz,  H-3’ + H-5’), 7.72 (1H, s, H-5), 7.65 (1H, d, J=8.4 Hz, H-8), 7.54 344 
(1H, d, J=8.4 Hz, H-7), 7.42 (2H, d, J=8.4 Hz, H-2’ + H-6’), 4.44 (2H, s, CH2), 3.99 (6H, s, 2 CH3). 345 
13C-NMR (DMSO-d6) δ: 166.87 (C), 149.91 (C),  149.72 (C), 142.70 (C), 136.35 (C), 135.63 (C), 346 
135.45 (C), 129.69 (2 CH), 127.46 (CH), 127.40 (C), 126.45 (2 CH), 126.10 (CH), 125.83 (CH), 347 
53.84 (2 CH3), 34.99 (CH2). LC/MS: 357 (M + H). Anal. Calcd for C19H16N2O4S: C, 60.66; H, 348 
4.53; N, 7.86; S, 9.00. Found C, 60.62; H, 4.58; N, 7.87; S, 9.05. 349 
4.1.5.3. 6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinic acid (9). Yield 88%. M.p. 205-206 350 
°C. νmax cm
-1: 1710; 1590. λmax nm: 330; 315; 302; 249; 212. 
1H-NMR (DMSO-d6) δ: 8.93 (1H, s, 351 













J=6.8 Hz, H-3’), 7.44 (1H, d, J=7.6 Hz, H-8), 4.64 (2H, s, CH2), 4.00 (6H, s, 2 CH3). 
13C-NMR 353 
(DMSO-d6) δ: 166.05 (C), 163.24 (C), 150.19 (CH), 149.93 (C), 149.73 (C), 136.93 (CH), 136.32 354 
(C), 136.29 (C), 135.61 (C), 127.68 (CH), 126.09 (CH), 125.89 (CH), 122.72 (C), 115.08 (CH), 355 
53.87 (2 CH3), 32.98 (CH2). LC/MS: 358 (M + H). Anal. Calcd for C17H15N3O4S: C, 57.13; H, 356 
4.23; N, 11.76; S, 8.97. Found C, 57.09; H, 4.25; N, 11.82; S, 9.01. 357 
4.1.6. General procedure for the preparation of diethyl N-{2-[(2,3-dimethoxyquinoxalin-6-358 
yl)methylthio]benzoyl}-L-glutamate (4) and of diethyl N-{6-[(2,3-dimethoxyquinoxalin-6-359 
yl)methylthio]nicotinoyl }-L-glutamate (10) 360 
A mixture of the suitable acid 3,9 (1.40 mmol), L-glutamic acid diethyl ester hydrochloride (1.54 361 
mmol), DEPC (1.54 mmol) and TEA (3.08 mmol) in 20 ml of dry DMF was stirred at room 362 
temperature, under N2, for 2 h. The obtained solution was poured in a 40 ml of a 3:1 mixture of 363 
ethyl acetate-toluene. This organic phase was washed with water (50 ml), then with a saturated 364 
solution of Na2CO3 (60 ml), with water again (50 ml) and finally with a saturated solution of NaCl 365 
(60 ml). After drying over Na2SO4, the solvent was removed by evaporation in vacuo to give 366 
compounds 4, 10 as yellow oils witch were purified by trituration with methanol. 367 
4.1.6.1. Diethyl N-{2-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoyl}-L-glutamate (4). Yield 368 
38%. M.p. 130-131 °C. νmax cm
-1: 3230; 1730; 1700; 1640; 1590; 1225. λmax nm: 315; 301; 233; 369 
197. 1H-NMR (DMSO-d6) δ: 8.72 (2H, d, NH), 7.72 (1H, s, H-5), 7.65 (1H, d, J=8.0 Hz, H-6’), 370 
7.55 (1H, d, J = 7.6 Hz, H-8), 7.48-7.43 (2H, m, H-7 + H-4’), 7.39 (1H, d, J=7.2 Hz, H-3’), 7.25 371 
(1H, d, , J=7.2 Hz, H-5’), 4.46-7.43 (1H, m, CH), 4.35 (2H, s, CH2S), 4.12 (2H, q, OCH2CH3), 372 
2.28-2.01 (2H, m, CH2), 1.99-1.79 (2H, m, CH2), 1.22-1.13 (6H, m, 2 CH3). 
13C-NMR (DMSO-d6) 373 
δ: 172.14 (C), 171.46 (C), 167.82 (C), 149.86 (C), 149.67 (C), 136.30 (C), 135.98 (C),135.54 (C), 374 
135.42 (C), 130.12 (CH), 128.12 (CH), 127.91 (CH), 127.70 (CH), 125.94 (CH), 125.10 (CH), 375 













13.99 (2 CH3). LC/MS: 542 (M + H). Anal. Calcd for C27H31N3O7S: C, 59.88; H, 5.77; N, 7.76; S, 377 
5.92 Found C, 59.93; H, 5.75; N, 7.82; S, 5.89. 378 
4.1.6.2. Diethyl N-{6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinoyl}-L-glutamate (10). 379 
Yield 39%. M.p. 110-111 °C. νmax cm
-1: 3330; 1730; 1600; 1630; 1220; 1090; 1020; 990. λmax nm: 380 
330; 315; 303; 273; 248;212.). 1H-NMR (CDCl3) δ: 8.86 (1H, s, H-6’), 7.86 (1H, d, J=8 Hz, Hz H-381 
4’), 7.74 (1H, s, H-5), 7.62 (1H, d, J=8.4 Hz, H-7), .46 (1H, d, J’=8 Hz, H-3’), 7.16 (1H, d, J=8.4 382 
Hz, H-8), 4.70-4.57 (1H, m, CH), 4.57 (2H, s, CH2S), 4.15 (2H, q, CH2CH3), 4.05 (8H, s, 2 CH3O + 383 
OCH2CH3), 2.47-2.37 (2H, m, CH2CH2), 2.13-2.04 (2H, m, CH2CH2), 1.23 (3H, t, CH3CH2). 1.16 384 
(3H, t, CH3CH2). 
13C-NMR (CDCl3) δ: 173.50 (C), 172.71 (C), 164.89 (C), 162.60 (C), 150. 7 (C), 385 
150.00 (C), 147.58 (CH), 137.11 (C), 136.48 (C), 135.99 (C), 135.33 (CH), 127.59 (CH), 126.60 386 
(CH), 126.44 (CH), 125.41 (C), 121.69 (CH), 61.85 (CH2), 61.01 (CH2), 54.24 (CH), 52.57 (2 387 
CH3), 34.38 (CH2), 30.51 (CH2), 26.86 (CH2), 14.16 (2 CH3). LC/MS: 543 (M + H). Anal. Calcd 388 
for C26H30N4O7S: C, 57.55; H, 5.57; N, 10.33; S, 5.91. Found C, 57.59; H, 5.54; N, 10.29; S, 5.92. 389 
4.1.7. General procedure for the preparation of the N-{2-[(2,3-dimethoxyquinoxalin-6-390 
yl)methylthio]benzoyl}-L-glutamic acid (5) and of N-{6-[(2,3-dimethoxyquinoxalin-6-391 
yl)methylthio]nicotinoyl]-L-glutamic acid (11) 392 
A mixture of 0.7 mmol of suitable diesther 4, 10 in 15 ml of ethanol and 8 ml of NaOH 1 N was 393 
stirred at room temperature for 3 h. After concentration in vacuo the remaining alkaline solution 394 
was diluted with water and made acidic with HCl 2N. Compounds 5, 11 precipitated from solution 395 
and were purified by crystallization from acetonitrile. 396 
4.1.7.1. N-{2-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]benzoyl}-L-glutamic acid (5). Yield 77%. 397 
M.p. 152-153 °C. νmax cm
-1: 3250; 1730; 1700; 1640; 1225; 1100; 1035; 990. λmax nm: 331; 317; 398 
249; 212. 1H-NMR (CDCl3) δ: 8.46 (1H, d, J=7.8 Hz, NH), 7.70 (1H, s, H-5), 7.66 (1H, d, J=8.4 399 
Hz, H-8), 7.52-7.49 (2H, m, arom), 7.42-7.15 (3H, m, arom), 4.57-4.48 (1H, m, CH), 4,30 (2H, s, 400 
CH2), 4.07 (6H, s, 2,3-OCH3), 2.50-1.90 (4H, m, CH2CH2). 













175.06 (C), 168.70 (C), 165.44 (C), 150.27 (C), 148.78 (C), 135.96 (C), 134.20 (C), 133.45 (C), 402 
129.46 (CH), 129.07 (CH), 127.68 (CH), 127.56 (CH), 54.89 (2 CH3), 52.45 (CH), 33.01 (CH2), 403 
30.96 (CH2), 26.19 (CH2). LC/MS: 486 (M + H). Analysis for C23H23N3O7S: C, 56.90; H, 4.78; N, 404 
8.66; S, 6.60. Found C, 56.94; H, 4.83; N, 8.71; S, 6.66. 405 
4.1.7.2. N-{6-[(2,3-dimethoxyquinoxalin-6-yl)methylthio]nicotinoyl]-L-glutamic acid (11). Yield 406 
83%. M.p. 101-102 °C. νmax cm
-1: 3300; 1735; 1700; 1640; 1590. λmax nm: 329; 315; 302; 271; 248; 407 
212. 1H-NMR (CDCl3) δ: 8.93 (1H, s, H-2’), 8.72 (1H, d, J=7.6 Hz, Hz H-8), .07 (1H, d, J=8.4 Hz, 408 
H-4’), 7.77 (1H, s, H-5), 7.67 (1H, d, J=6.4 Hz, H-3’), 7.44 (1H, d, J’=8.4 Hz, H-7), 4.64 (2H, s, 409 
CH2S), 4.45-4.37 (1H,m, CH), 4.01 (6H, s, 2 CH3), 2.11-2.07 (2H, m, CH2), 2.06-1.91 (2H, m, 410 
CH2). 
13C-NMR (CDCl3) δ: 173.60 (C), 173.06 (C), 164.62 (C), 161.29 (C), 155.01 (C), 150.15 (C), 411 
148.54 (CH), 136.81 (C), 136.20 (C), 135.59 (CH), 132. 5 (C), 127.66 (CH), 126.07 (CH), 125.68 412 
(CH), 125.56 (C), 54.11 (2 CH3), 52.45 (CH), 32.90 (CH2), 30.56 (CH2), 26.12 (CH2). LC/MS: 487 413 
(M + H). Analysis for C22H22N4O7S: C, 54.32; H, 4.56; N, 11.52; S, 6.59. Found C, 54.28; H, 4.58; 414 
N, 11.49; S, 6.63.  415 
4.2. Cells and viruses 416 
Cell lines were purchased from American Type Culture Collection (ATCC). Cell lines supporting 417 
the multiplication of RNA and DNA viruses were the following: CD4+ human T-cells containing 418 
an integrated HTLV-1 genome (MT-4); Madin Darby Bovine Kidney (MDBK) [ATCC CCL 22 419 
(NBL-1) Bos taurus]; Baby Hamster Kidney (BHK-21) [ATCC CCL 10 (C-13) Mesocricetus 420 
auratus] and Monkey kidney (Vero-76) [ATCC CRL 1587 Cercopithecus aethiops]. Human 421 
Immunodeficiency Virus type-1 (HIV-1) IIIB laboratory strain was obtained from the supernatant 422 
of the persistently infected H9/IIIB cells (NIH 1983). Viruses representative of ssRNA+ were: i) 423 
Flaviviridae: yellow fever virus (YFV) [strain 17-D vaccine (Stamaril Pasteur J07B01)], bovine 424 
viral diarrhoea virus (BVDV) [strain NADL (ATCC VR-534)]; ii) Picornaviridae: enterovirus B 425 













(Sb-1), Sabin strain Chat (ATCC VR-1562)]. Viruses representative of ssRNA- were: iii) 427 
Paramyxoviridae: human respiratory syncytial virus (RSV) [strain A2 (ATCC VR-1540)]; iv) 428 
Rhabdoviridae: vesicular stomatitis virus (VSV) [lab strain Indiana (ATCC VR 1540)]. The virus 429 
representative of dsRNA was: iv) Reoviridae: reovirus type-1 (Reo-1) [simian virus 12, strain 3651 430 
(ATCC VR-214)]. DNA virus representatives were: v) Poxviridae: vaccinia virus (VV) [vaccine 431 
strain Elstree-Lister (ATCC VR-1549)]; vi) Herpesviridae: human herpes 1 (HSV-1) [strain KOS 432 
(ATCC VR-1493)]. 433 
4.3. Cytotoxicity assays 434 
Exponentially growing MT-4 cells were seeded at an initial density of 4×105 cells/ml in 96-well 435 
plates in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS), 100 units/ml 436 
penicillin G and 100 µg/ml streptomycin. MDBK and BHK cells were seeded in 96-well plates at 437 
an initial density of 6×105 and 1×106 cells/ml, respectively, in Minimum Essential Medium with 438 
Earle’s salts (MEM-E), L-glutamine, 1 mM sodium pyruvate and 25 mg/l kanamycin, supplemented 439 
with 10% horse serum (MDBK) or 10% foetal bovine serum (FBS) (BHK). Vero-76 cells were 440 
seeded in 96-well plates at an initial density of 4×105 cells/ml, in Dulbecco’s Modified Eagle 441 
Medium (D-MEM) with L-glutamine and 25 mg/l kanamycin, supplemented with 10% FBS. Cell 442 
cultures were then incubated at 37 °C in a humidifie , 5% CO2 atmosphere, in the absence or 443 
presence of serial dilutions of test compounds. Cell viability was determined after 48-96 hrs at 37 444 
°C by MTT method for MT-4, MDBK, Vero-76 and BHK [40]. 445 
4.4. Antiviral assays 446 
Compound’s activity against HIV-1 was based on inhibition of virus-induced cytopathogenicity in 447 
exponentially growing MT-4 cell acutely infected with a multiplicity of infection (m.o.i.) of 0.01. 448 
Compound’s activity against YFV and Reo-1 was based on inhibition of virus-induced 449 
cytopathogenicity in BHK-21 cells acutely infected with a m.o.i. of 0.01. Compound’s activity 450 
against BVDV was based on inhibition of virus-induced cytopathogenicity in MDBK cells acutely 451 













by the MTT method, as described earlier [41]. Compound’s activity against CV-B5, Sb-1, VSV, 453 
VV, HSV-1 and RSV was determined by plaque reduction assays in infected Vero-76 cell 454 
monolayers, as described earlier [41] and the cytotoxicity of test compounds was determined in 455 
parallel on the same 96-well plate. Concentrations resulting in 50% or 90% inhibition (CC50 or 456 
EC50/EC90) were determined by linear regression analysis. 457 
4.5. Yield reduction assay 458 
Vero-76 cells were inoculated with CV-B5 at a m.o.i. f 0.1 in maintenance medium and tested 459 
compounds at not cytotoxic concentrations. Following 2 hours adsorption period at 37 °C and 5% 460 
CO2, the inoculum was removed and replaced with fresh medium containing the same concentration 461 
of compounds 6. After 72 hours at 37 °C and 5% CO2 each sample was harvested and diluted with 462 
serial passages, starting from 10-1 up to 10-8. The titre of the serial dilutions of the virus-containing 463 
supernatant was determined by standard plaque assay, counting the number of obtained plaques in 464 
at least two different dilutions for each concentration. Pleconaril was used as reference compound. 465 
4.6. Virucidal activity assay 466 
A CV-B5 suspension containing 5×105 PFU/ml was incubated with or without different 467 
concentrations of compound for 1 hour at 37 °C. At the end of incubation, the residual infectivity 468 
was determined by plaque assay in Vero-76 cells. 469 
4.7. Time-of-drug-addition experiment 470 
Vero-76 cells were infected with CV-B5 at m.o.i. of 0.3. 6 (1 µM) was added at 2 h prior to 471 
infection, during the infection and at varying times post infection. The confluent monolayers of 472 
Vero-76 cells, seeded in 24-well tissue culture plates, were infected and incubated for 3 days as 473 
previously described. Monolayers were collected and the viral titre was determined by plaque assay. 474 
Medium containing 6 was: i) added at -2 to 0 (pretreatment) and then removed; ii) added at the time 475 
of infection (time 0) and removed or maintained; iii) added at 2, 4, 6, 8 and 12 hours post infection. 476 
Pleconaril was used as reference compound. 477 













Vero-76 cells grown in 24-well plate were infected with CV-B5, with a m.o.i. of 0.1, in the 479 
presence or absence of compound 6. Multiwell were incubated for 60 min at 4 °C. Medium 480 
containing unadsorbed virus was then removed, cells were washed twice with PBS and covered 481 
with MEM containing 1% methylcellulose. Plaques were counted after 24 hrs of incubation at 37 482 
°C. 483 
4.9. Molecular modeling 484 
Compound 6 was parameterized according to a consolidated procedure [17]. The available 3D 485 
model structure of the CV-B5 protomer was downloaded from RSCB Protein Data Bank database 486 
(pdb code = 1OOP) and optimized via energy relaxation/MD simulations in solution [42-44]. 487 
To study the mechanism of VP1 binding, compound 6 was docked into the VP1binding pocket 488 
within the protomer complex, and the Molecular Mechanics/Poisson Boltznam Surface-Area 489 
(MM/PBSA) [45-47] scoring was adopted to estimate its affinity against the viral target.  490 
In detail, the resulting protein/inhibitor docked conformations were clustered and visualized; then, 491 
in the absence of any relevant crystallographic information for the specific compound, the structure 492 
of the complex characterized by the lowest interaction energy in the prevailing cluster was selected 493 
for further modeling. The selected VP1/6 complex was then solvated in a TIP3P [48] water box and, 494 
then, the required amount of Na+ nd Cl- ions were added to neutralize the system and to mimic 495 
physiological salt conditions (150 mM), removing eventual overlapping water molecules. The 496 
solvated systems were subjected to a combination of steepest descent/conjugate gradient 497 
minimization of the potential energy, during which all bad contacts were relieved. The relaxed 498 
system was then gradually heated to 37 °C in three int rvals by running constant volume-constant 499 
temperature (NVT) MD simulation. Subsequently, 10 ns MD simulations under isobaric-isothermal 500 
(NPT) conditions were conducted to fully equilibrate each solvated compound. The SHAKE 501 
algorithm with a geometric tolerance of 5×10-4 Å was imposed on all covalent bonds involving 502 
hydrogen atoms. Temperature control was achieved using the Langevin temperature equilibration 503 













to treat the long-range electrostatics. At this point, this MD runs was followed by other 50 ns of 505 
NVT MD simulation. All simulations were carried out sing the Pmemd modules of Amber 14 [50], 506 
running on a hybrid CPU/GPU calculation cluster. 507 
The binding free energy, ∆Gbind, between the inhibitor and the VP1 protein was then estimated by 508 
resorting to the MM/PBSA approach implemented in Amber 14. According to this well validated 509 
methodology, the free energy was calculated for each molecular species (complex, receptor, and 510 
ligand), and the binding free energy was computed as the difference:  511 
∆Gbind = GVP1/6 - (GVP1 + G6) = ∆EMM + ∆GSOL -T∆S  512 
in which ∆EMM represents the molecular mechanics energy (contributed by van der Waals and 513 
electrostatic interactions), ∆GSOL includes the solvation free energy and T∆S is the conformational 514 
entropy upon ligand binding. The per residue binding free energy decomposition (∆Hbind,res) was 515 
performed exploiting the MD trajectory of protein/compound complex, with the aim of identifying 516 
the key residues involved in the ligand/protein interaction. This analysis was carried out using the 517 
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 672 
Figure legends 673 
Figure 1. Chemical structure of quinoxaline derivatives endowed with antiviral activity.  674 
Figure 2. Chemical structure of quinoxaline derivatives 2a-e, 3-11. 675 
Figure 3. Dose-dependent reduction of CV-B5 titre in the presence of different concentrations of 6 676 
(dark bars), compared with untreated infected control (striped bars); pleconaril was used as 677 
reference compound (light bars). Data represent mean ± S.D. values of two independent 678 
determinations. 679 
Figure 4. 6 inhibition of CV-B5 in a time of drug addition experiment. The addition of 6 at 0 and 2 680 
hours significantly reduces the virus titre, while when added 4 hours or more post infection, 6 is not 681 













(triangles) and with a reference compound (circles) in the same experimental conditions. The results 683 
are representative of two independent experiments, ach one performed in duplicate. 684 
Figure 5. Overall representation of the optimized and solvated CV-B5 protomer with compound 6 685 
docked into the pocket of VP1. The inhibitor is in f rebrick sphere representation while the 686 
protomer is represented by its different monomer highlighted in colors as follows: VP1, green;, 687 
VP2, blue; VP3, dark magenta; and VP4, gold. 688 
Figure 6. (A) Details of compound 6 in the VP1 binding pocket of the CV-B5 protomer complex. 689 
Compound 6 is depicted as atom-colored sticks-and-balls (C, gray; N, blue, Cl, green; S, yellow). 690 
Hydrogen bonds are highlighted as black broken lines. The side chains of all VP1 residues mainly 691 
involved in the interaction with 6 are highlighted as colored sticks: I94, L106, F114, L116, L118, 692 
Y191, and M215, magenta; T96 and R103, green; R97 and F239, cyan. Hydrogen atoms, water 693 
molecules, ions and counterions are omitted for clarity. (B) Per residue binding enthalpy 694 
decomposition DHbind,res for compound 6 in complex with VP1. The corresponding enthalpic 695 
contribution for each critical protein residues are colored according to the specific underlying 696 
interactions interactions: I94, L106, F114, L116, L118, Y191, and M215, hydrophobic interaction 697 
(magenta); T96 and R103, hydrogen bond (green); R97 and F239, p interactions (cyan). 698 
Scheme 1. Synthesis scheme of 2,3-dimethoxy-6-[(arylthio)methyl]quinoxaline derivatives 2a-e, 3-699 
5. Reaction condition: i) DMF, Cs2CO3, 70 °C, 2 h; ii) EtOH/H2O, NaOH 1M, 70 °C, 7 h; iii) L-700 
glutamic acid diethyl ester hydrochloride, DMF, DEPC, TEA, r.t., 2 h; iv) EtOH, NaOH 1M, r.t., 3 701 
h. 702 
Scheme 2. Synthesis of 2,3-dimethoxy-6-[(phenylthio)methyl]quinoxaline derivatives 6-7 and 2,3-703 
dimethoxy-6-[(pyridin-2-ylthio)methyl]quinoxaline derivatives 8-11. Reaction condition: i) DMF, 704 
r.t., 5 days; ii) EtOH/H2O, NaOH 1M, 70 °C, 7 h; iii) L-glutamic acid diethyl ester hydrochloride, 705 
DMF, DEPC, TEA, r.t., 2 h; iv) EtOH, NaOH 1M, r.t., 3 h. v) DMF, Cs2CO3, 70 °C, 2 h; vi) EtOH, 706 























































































































New quinoxaline derivatives were tested against different RNA and DNA viruses. 
Three compounds emerged for their very potent antiviral activity against CV-B5. 
Compound 6 inhibits by targeting the penetration or an early event of life cycle. 
Molecular simulations revealed that a possible viral target is the viral capsid protein VP1. 
 
